Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

1. WO2004106532 - MODIFIED POLYPEPTIDES FOR TARGETING CELL-ENTRY OF THE ADENOVIRUSES OF SUBTYPE B

Publication Number WO/2004/106532
Publication Date 09.12.2004
International Application No. PCT/EP2004/005762
International Filing Date 27.05.2004
IPC
A61K 38/17 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
C07K 14/705 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
C07K 16/46 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
C12N 15/62 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
C07K 2319/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
C07K 2319/32
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
32fusions with soluble part of a cell surface receptor, "decoy receptors"
C07K 2319/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
33fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Applicants
  • CYTOS BIOTECHNOLOGY AG [CH]/[CH] (AllExceptUS)
  • BEERLI, Roger, R [CH]/[CH] (UsOnly)
  • BACHMANN, Martin, F. [CH]/[CH] (UsOnly)
Inventors
  • BEERLI, Roger, R
  • BACHMANN, Martin, F.
Agents
  • WICHMANN, Hendrik
Priority Data
03011184.327.05.2003EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) MODIFIED POLYPEPTIDES FOR TARGETING CELL-ENTRY OF THE ADENOVIRUSES OF SUBTYPE B
(FR) POLYPEPTIDES MODIFIES DESTINES A CIBLER L'ENTREE DANS LES CELLULES DES ADENOVIRUS DE SOUS-TYPE B
Abstract
(EN) This invention relates to modified polypeptides comprising two functional components: first, a polypeptide derived from the extracellular region of CD46 as a specific binding site for adenoviruses of the subgroup B, and second, a component capable of binding to a cell surface molecule. Such modified polypeptides are able to direct adenovirus­infection specifically to cells having said cell surface molecule on their surface. The invention relates to nucleic acid sequences encoding fusion proteins comprising a) a polypeptide derived from the extracellular domain of CD46 and b) a heterologous polypeptide, methods for the production of the modified polypeptides and suitable recombinant expression vectors and host cells. Pharmaceutical compositions comprising the modified polypeptide of the invention are useful together with recombinant, genetically engineered adenovirus of subtype B for the treatment and prophylaxis of disorders and diseases, like cancer.
(FR) L'invention concerne des polypeptides modifiés comprenant deux composants fonctionnels: premièrement, un polypeptide dérivé de la région extracellulaire de CD46 comme site de liaison spécifique des adénovirus du sous-groupe B, et deuxièmement, un composant capable de se lier à une molécule de surface cellulaire. De tels polypeptides modifiés sont capables de diriger l'infection à l'adénovirus spécifiquement vers les cellules ayant, à leur surface, cette molécule de surface cellulaire. L'invention concerne des séquences d'acide nucléique codantes pour les protéines hybrides contenant a) un polypeptide dérivé du domaine extracellulaire de CD46 et b) un polypeptide hétérologue, des procédés de production des polypeptides modifiés et des vecteurs d'expression recombinants adéquats et des cellules hôtes. Les compositions pharmaceutiques contenant le polypeptide modifié de l'invention sont utiles avec l'adénovirus recombinant, génétiquement modifié de sous-type B pour le traitement et la prévention de troubles et maladies, comme le cancer.
Related patent documents
US2007065408This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau